When a pandemic reshapes a health system, the wounds it leaves are not always visible in the crisis itself — they appear later, in the women who waited too long, in the surgeries that never happened, in the survival rates that quietly fell. A study tracking 2,522 women through Johannesburg's public hospitals found that South Africa's prolonged Covid-19 lockdowns accelerated an already troubling pattern of late-stage breast cancer diagnoses, and that even after restrictions lifted, the system never fully recovered. The damage settled into the infrastructure itself — in overwhelmed theatres, in
Pandemic's Shadow Lingers: Johannesburg Breast Cancer Care Never Fully Recovered
Women with delayed breast cancer treatment face 11% increased mortality risk per additional month of delay; three-year survival drops from 85% to 79% for those delayed beyond three months.
The system is now treating more women with fewer resources per patient.
Mark
So the pandemic disrupted cancer care everywhere. What makes Johannesburg's story different?
Mimi
The lockdown lasted 27 months—longer than almost anywhere else—and the study shows the system never fully recovered. Women are still waiting longer to seek care, and treatment delays persisted even after restrictions ended.
Luke
But the diagnostic interval actually stayed stable during the pandemic. Why?
Mimi
Surgeons personally triaged patients at the breast unit instead of delegating to nurses, which kept diagnosis moving. That's a bright spot.
Mark
And after the pandemic ended, things got worse?
Mimi
Yes. Patient volumes jumped 20 percent, but the hospitals didn't hire more staff or build more operating theatres. So even though restrictions lifted, women still waited longer for surgery.
Luke
The study says late-stage diagnoses partially recovered. What does "partially" mean in numbers?
Mimi
Before the pandemic, 50 percent at one hospital and 63 percent at the other had advanced disease. During lockdown, it climbed to 60 and 69 percent. After, it fell to 53 and 55 percent. So they're still above where they started.
Mark
Is the delay in seeking care the main problem?
Mimi
It's part of it. Women wait an average of two months after noticing symptoms before going to a clinic, and they say they didn't think the lump was serious. But even if they got there faster, the hospitals can't treat them fast enough.
Luke
The study relies on women's memory for when they first noticed symptoms. How reliable is that?
Mimi
The authors acknowledge it's a source of bias. But their sensitivity analyses supported the findings, so the core story holds.
Mark
What would actually fix this?
Mimi
The researchers call for community education campaigns, streamlined referrals to bypass secondary hospitals, and public-private partnerships to expand surgical capacity. Without that investment, the system will keep missing international standards.
O Pulso
- Late-stage breast cancer diagnoses surged during lockdown — from already alarming baselines of 50–63% to as high as 69% — and never fully returned to pre-pandemic levels even two years after restrictions ended.
- Women are waiting longer before seeking care, with the median delay between noticing symptoms and visiting a clinic more than doubling at one hospital, driven by the persistent belief that breast symptoms are not serious.
- Patient volumes have surged more than 20% since the pandemic, but staffing and surgical capacity have not kept pace, forcing hospitals to substitute chemotherapy for surgery and leaving international treatment benchmarks unmet in every measured period.
- Each additional month of treatment delay carries an 11% increase in mortality risk, and women delayed beyond three months see three-year survival drop from 85% to 79% — making the system's stagnation a measurable death toll.
- Researchers are calling for community education campaigns, streamlined referral pathways directly to tertiary centers, and public-private partnerships to expand surgical capacity before the rising burden of breast cancer outpaces any remaining capacity to respond.
When a pandemic reshapes a health system, the wounds it leaves are not always visible in the crisis itself — they appear later, in the women who waited too long, in the surgeries that never happened, in the survival rates that quietly fell. A study tracking 2,522 women through Johannesburg's public hospitals found that South Africa's prolonged Covid-19 lockdowns accelerated an already troubling pattern of late-stage breast cancer diagnoses, and that even after restrictions lifted, the system never fully recovered. The damage settled into the infrastructure itself — in overwhelmed theatres, in communities still uncertain whether a lump is worth the journey — leaving a city's most vulnerable women navigating a health system permanently altered by a crisis that has officially ended.
When South Africa imposed one of the world's longest national lockdowns in March 2020, hospitals in Johannesburg redirected staff and resources toward the viral emergency. For women who noticed a lump in their breast, the consequences were quiet, cumulative, and in many cases permanent. A study published in BMC Cancer followed 2,522 women across two major academic hospitals — Chris Hani Baragwanath in Soweto and Charlotte Maxeke in the city center — through three distinct periods: before the pandemic, during lockdown, and after restrictions lifted in mid-2022.
The most alarming finding was how advanced the disease had become by the time women arrived. Before the pandemic, roughly half to two-thirds of patients at both hospitals presented with stage III or IV cancer — already far from the WHO's target of 60% early-stage diagnoses. During lockdown, those figures climbed higher still, reaching 69% at Maxeke. After restrictions ended, the numbers fell only partially, settling at 53–55%. The system never approached international standards in any period.
The delays began long before women reached the hospital. At Baragwanath, the median time between noticing symptoms and seeking care more than doubled after the pandemic and never reversed. The most common reason, cited by up to 89% of women, was the belief that their symptoms were not serious — a perception the pandemic appears to have deepened. Fear of Covid-19 exposure on public transport and in crowded clinics likely compounded the hesitation.
Once women arrived, diagnosis proved surprisingly resilient — surgeons at Baragwanath personally triaged patients, which may have helped maintain speed. But treatment initiation told a grimmer story. Median time from diagnosis to starting treatment lengthened and stayed longer even after the pandemic ended. Elective surgery restrictions reduced the proportion of women receiving operations, a decline that worsened post-pandemic regardless of disease stage. Neoadjuvant chemotherapy rose sharply as a substitute, and hormone therapy became a holding measure when operating theatres were unavailable.
The human cost is concrete: women who received surgery within three months achieved 85% three-year survival, compared with 79% for those delayed beyond that threshold — and each additional month of delay raised mortality risk by 11%. Patient volumes have since surged more than 20% without matching increases in staff or infrastructure. The researchers argue that recovery requires both community-level campaigns to change how women perceive breast symptoms and structural reforms — streamlined referrals, expanded surgical capacity, and public-private partnerships — to prevent a system already under strain from falling further behind.
In March 2020, when the World Health Organization declared a pandemic, South Africa imposed one of the world's longest national lockdowns, lasting more than two years until June 2022. Hospitals shuttered wards, pulled staff toward the viral emergency, and rationed resources. For women in Johannesburg's public health system who felt a lump in their breast, the consequences were measurable and, in many cases, permanent. A study published this year in BMC Cancer tracked more than 2,500 women through two major academic hospitals and found a health system that partially bounced back but never returned to where it started.
Researchers led by Rebaone Petlele and Maureen Joffe at the University of the Witwatersrand analyzed data from Chris Hani Baragwanath Academic Hospital in Soweto and Charlotte Maxeke Johannesburg Academic Hospital in the city center. They followed 2,522 women with confirmed invasive breast cancer across three periods: before the pandemic (April 2017 to March 2019), during lockdown (April 2020 to March 2022), and after restrictions lifted (July 2022 to June 2024). The researchers measured three critical intervals: how long women waited after noticing symptoms before seeking care, how long diagnosis took once they reached a clinic, and how long between diagnosis and starting treatment.
The most striking finding concerns how advanced the disease was when women arrived. Before the pandemic, half the patients at Baragwanath and nearly two-thirds at Maxeke presented with stage III or IV cancer—already alarming numbers. During lockdown, those figures climbed to 60 percent and 69 percent. Even after the pandemic ended and restrictions lifted, the proportions only partially fell back, settling at 53 percent and 55 percent. The World Health Organization's Global Breast Cancer Initiative calls for at least 60 percent of diagnoses to occur at stage I or II. Johannesburg's public hospitals never approached that target in any period, meaning the majority of women still arrived with disease that had spread beyond the breast.
The delays happened before women even reached the hospital. At Baragwanath, the median time between noticing symptoms and seeking care stretched from 0.8 months before the pandemic to 2.0 months afterward—a deterioration that never reversed. At Maxeke, this pre-contact interval remained relatively stable. The most common reason women delayed seeking care, cited by 75 to 89 percent depending on hospital and time period, was the belief that breast symptoms were not serious. During the pandemic, this proportion peaked. Fear of catching Covid-19 on public transport and in crowded clinics likely deepened the hesitation. Fewer than 70 percent of women reached the health system within three months of noticing symptoms in any period, with Maxeke's rate as low as 45 to 58 percent.
Once women arrived at the hospital, the diagnostic process proved surprisingly resilient. At Baragwanath, the median time from first contact to pathology-confirmed diagnosis held steady at 1.8 months across all three periods. At Maxeke, a rise to 2.0 months during the pandemic was not statistically significant. At Baragwanath, surgeons personally triaged patients for both breast symptoms and Covid-19 risk at the tertiary surgical breast unit—a task normally handled by triage nurses—which may have accelerated diagnosis. Yet between 27 and 41 percent of women still required more than two months from first contact to diagnosis, and the study confirmed that delays exceeding three months in this combined journey were linked to late-stage disease at presentation.
Treatment initiation told a grimmer story. At Baragwanath, the median time from diagnosis to starting surgery, chemotherapy, or hormone therapy lengthened from 1.6 months before the pandemic to 2.0 months during it and remained at 2.0 months afterward. The national suspension of elective surgery and restricted operating theatre availability reduced the proportion of women receiving surgery, a decline that worsened after the pandemic ended regardless of how advanced their cancer was. Neither hospital ever met the European Society of Breast Cancer Specialists' benchmark of starting treatment within eight weeks of diagnosis in 80 percent of patients. The pandemic also shifted treatment strategy: neoadjuvant chemotherapy—giving drugs before surgery to shrink tumors—rose from 35 percent of patients before Covid-19 to 54 percent at Baragwanath and from 52 to 62 percent at Maxeke. Hormone therapy became a holding strategy when operating theatres were unavailable.
The human cost of these delays is not theoretical. Earlier analyses of the same patient cohort showed that women who had surgery within three months of diagnosis achieved 85 percent three-year overall survival, compared with 79 percent for those delayed beyond three months. For every additional month of delay, mortality risk climbed 11 percent. The stakes compound because patient volumes at both hospitals have surged more than 20 percent since the pandemic compared with pre-pandemic levels, yet staffing and infrastructure have not grown to match. The system is now treating more women with fewer resources per patient. The researchers argue that intervention is needed at two levels: in communities, aggressive campaigns to encourage breast self-examination and dispel the myth that small or painless lumps can be safely ignored; within hospitals, streamlined referrals that send suspected breast cancer cases directly to tertiary centers rather than through secondary hospitals, and public-private partnerships to expand surgical and chemotherapy capacity. Without substantial investment in human resources and infrastructure, they conclude, neither Johannesburg hospital is likely to meet international standards or manage the rising burden of breast cancer in South Africa, a country with no formal public screening program and mammography reserved only for women with symptoms.
Citações Notáveis
Without substantial investment in human resources and infrastructure, neither Johannesburg hospital is likely to meet international standards or cope with the steadily rising burden of breast cancer in South Africa.— Study authors Petlele and Joffe
Quer a matéria completa?
Leia o original em Bioengineer.org ↗